Epigral Ltd — earnings calls
2 quarters summarised from transcripts filed with the exchange, every statement cited. Newest first.
Epigral reported Q1 FY27 revenue growth of 15% to Rs 709 crore and EBITDA margin of 25%, aided by higher sales volumes and improved realizations despite disruptions from the West Asia conflict affecting shipping and raw material costs. The Board approved capex for two new projects, a 125,000 tonnes per annum Epoxy Resin and Formulations facility and a multipurpose plant for chlorotoluene and epichlorohydrin derivatives, both targeted to have pilot facilities operational by Q2 FY27. Management discussed capacity utilization across segments, ECU and ECH realizations, and the rationale for backward integration and export strategy for the new capacities.
Epigral reported its highest ever quarterly revenue of Rs 736 crore in Q4 FY26, with EBITDA up 64% quarter-on-quarter to Rs 169 crore and PAT at Rs 82 crore. Management attributed the improvement to 15% quarter-on-quarter volume growth, completion of major maintenance work, and normalized raw material prices, while full-year FY26 revenue declined 1% due to a 4% drop in volumes. Management also discussed the impact of West Asia conflict on raw material and finished goods prices, and progress on Epichlorohydrin and CPVC capacity expansion projects expected to be commissioned in Q2 FY27.